Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 3;13:1015585. doi: 10.3389/fimmu.2022.1015585

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Blagovic, Smith, Ramakrishnan, Moore, Soto, Thompson, Stockmann, Kruszelnicki, Thakkar, Murray, Torres, Wondimagegnhu, Yi, Dadgar, Paracha, Page, Clear, Chaudhry, Myint, Bridgen, Gilbert, Seidl, Sharei, Loughhead, Bernstein and Yarar

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Synergistic therapeutic effect of AACs and chemotherapy combination. (A) Schematic of Cisplatin and AAC-E7 dosing. Early (two doses: day 7, 9 post TC-1 implant) and late (two doses: day 17, 24 post TC-1 implant) Cisplatin dosing was administered as monotherapy or in combination with AAC-E7. (B) Tumor growth curves for PBS, AAC-E7 and Cisplatin monotherapy, or combination therapy. The figures show the same PBS and AAC-E7 monotherapy treatment groups overlayed with early (left) and late (right) Cisplatin dosing. (C) Spider plots of individual mice per each treatment group. (D) Median survival (n = 10 mice per group). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, Mantel-Cox test for median survival.